February 3, 2011 / 7:04 AM / 8 years ago

Sanofi could announce Genzyme deal next week - report

PARIS (Reuters) - French drugmaker Sanofi-Aventis (SASY.PA) could announce a deal to buy U.S. biotech Genzyme GENZ.O early next week if final negotiations between the companies go smoothly, Le Figaro reported on Thursday.

Sanofi will offer a minimum of $72 or $73 a share in cash, as well as a contingent value right (CVR) based on the performance of experimental multiple sclerosis drug Lemtrada worth between $2 and $5 a share, the newspaper said. Genzyme has rejected Sanofi’s initial $18.5 billion (11.4 billion pounds) offer, worth $69 a share, which the French group has extended until February 15.

Sanofi this week gained access to detailed financial information about Genzyme as the two agreed in principle on the terms of a takeover, raising expectations that a final deal can be hammered out in the near term.

Sanofi has agreed to raise its bid to the low $70s-per-share range, plus the CVR milestone payment, a source familiar with the situation said earlier this week, but it did not raise the offer as high as the $75 per share value Genzyme had sought.

The final valuation could be in the “very high $70s” including the CVR, a second source said.

Sanofi is due to publish its results for 2010 on Wednesday, when it is seen posting a 3.2 percent drop in underlying earnings per share for the fourth quarter, excluding items such as amortisation and litigation costs, according to the average of 13 estimates in a Reuters poll of analysts.

Reporting by James Regan; Editing by Will Waterman

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below